Investment Rating - The investment rating for the company is "Buy-A" with a target price of 22.20 CNY per share, maintaining the rating [1][5]. Core Views - The company experienced a temporary decline in profit in H1 2024 due to various factors including reduced individual account balances and delays in the implementation of coordinated medical insurance [2][3]. - Revenue for H1 2024 was 4.485 billion CNY, a year-on-year increase of 3.40%, while net profit attributable to shareholders was 63 million CNY, a year-on-year decrease of 60.23% [2][3]. - The company is actively expanding its store network, with a total of 5,444 stores as of H1 2024, indicating stable growth in new and recently opened stores [4]. Financial Performance Summary - Revenue breakdown for H1 2024: - Prescription drugs: 1.572 billion CNY (+4.19%) - Over-the-counter drugs: 1.698 billion CNY (+7.23%) - Medical devices: 315 million CNY (-14.95%) - Health foods: 214 million CNY (-8.46%) - Traditional Chinese medicine: 165 million CNY (-12.82%) [3]. - Forecasted net profit for 2024-2026 is expected to be 174 million CNY, 201 million CNY, and 230 million CNY respectively, with an estimated EPS of 1.11 CNY for 2024 [5][7]. - The company’s financial metrics indicate a projected PE ratio of 20 times, with a target price of 22.20 CNY per share [5][7]. Store Network Expansion - The company continues to enhance its chain store service network, with 254 new stores built and 81 acquired in H1 2024 [4]. - The age structure of stores shows that 12.34% are less than one year old, 9.22% are two years old, and 78.43% are over two years old, suggesting a stable growth in profitability potential [4].

Investment Rating - The investment rating for the company is "Buy - A" with a 6-month target price of 7.50 CNY [4][8]. Core Views - The company reported a revenue of 729 million CNY for the first half of 2024, representing a year-on-year growth of 11.99%, and a net profit attributable to the parent company of 121 million CNY, up 42.84% year-on-year [1][2]. - The equipment segment showed steady growth, with revenue from power transmission and transformation equipment reaching 690 million CNY, a year-on-year increase of 12.22%. The gross margin for this segment improved to 38.21%, up 2.90 percentage points year-on-year [2][3]. - The engineering segment's revenue for the first half of 2024 was 28 million CNY, reflecting a year-on-year growth of 14.32%, aided by reduced operating costs [2]. Summary by Sections Financial Performance - In Q2 2024, the company achieved revenue of 475 million CNY, a year-on-year increase of 12.19%, and a net profit of 92 million CNY, up 41.95% year-on-year [1]. - The company expects revenues of 1.93 billion CNY, 2.62 billion CNY, and 3.46 billion CNY for 2024, 2025, and 2026 respectively, with growth rates of 29.1%, 35.7%, and 32.2% [7][9]. Market Position and Orders - The company secured significant orders from the State Grid, totaling 261 million CNY, 222 million CNY, 271 million CNY, and 233 million CNY across four bidding rounds [3]. - New product lines, including 500kV combined electrical appliances, have contributed to a strengthened product portfolio and improved market position [3]. Valuation Metrics - The company is projected to have a PE ratio of 24 times for comparable companies in 2024, while the company itself is given a PE of 15 times, leading to a target price of 7.50 CNY [8][10].

Investment Rating - The investment rating for the company is "Buy - A" with a 6-month target price of 7.05 CNY, compared to the current stock price of 5.24 CNY [3]. Core Views - The company demonstrated resilient operational performance with steady revenue and profit growth in H1 2024, achieving revenue of 1.14 trillion CNY (up 2.81% YoY) and a net profit of 29.45 billion CNY (up 1.65% YoY) [1]. - The infrastructure segment's revenue and new contract signing ratios are continuously improving, with overseas business new contracts doubling [1]. - The company is focusing on optimizing its business structure, with an increase in the proportion of industrial and infrastructure projects [1][2]. Summary by Sections Revenue and Profitability - In H1 2024, the company reported revenue of 1.14 trillion CNY, with a net profit of 29.45 billion CNY, reflecting a year-on-year increase of 2.81% and 1.65% respectively [1]. - The gross profit margin for the company was 9.4%, with improvements noted in the real estate sector [2][7]. Business Segments - The infrastructure business generated revenue of 269.47 billion CNY in H1 2024, up 11.7% YoY, accounting for 23.5% of total revenue [1]. - The construction segment's new contract signing amounted to 2.29 trillion CNY, a 13.7% increase YoY, with significant growth in energy, water, and environmental projects [1]. - The real estate development and investment segment saw revenue of 116.39 billion CNY, although it experienced a decline of 8.7% YoY [2]. Financial Forecasts - The company is projected to achieve revenues of 24.47 trillion CNY, 26.30 trillion CNY, and 28.14 trillion CNY for 2024, 2025, and 2026 respectively, with expected growth rates of 8.0%, 7.5%, and 7.0% [7][8]. - Net profits are forecasted to be 58.65 billion CNY, 63.48 billion CNY, and 68.52 billion CNY for the same years, with growth rates of 8.1%, 8.2%, and 7.9% [7][8].

Investment Rating - The investment rating for the company is maintained at Buy-A with a target price of 33.60 CNY, corresponding to a dynamic P/E ratio of 30.00x for 2024 [6][7]. Core Views - The company has shown significant sales growth driven by demand recovery, with a 30.36% year-on-year increase in revenue for H1 2024, reaching 3.427 billion CNY, and a 40.26% increase in net profit, amounting to 1.026 billion CNY [3]. - The electronic component materials business has experienced rapid growth, with revenue of 1.444 billion CNY in H1 2024, reflecting a 56.71% year-on-year increase, supported by improved utilization rates and stabilized product prices [4]. - The communication industry is evolving rapidly, and the company is adapting its product strategy accordingly, achieving a revenue of 1.221 billion CNY in optical communication components for H1 2024, which is a 30.99% year-on-year increase [5]. Summary by Sections Financial Performance - In Q2 2024, the company achieved a revenue of 1.864 billion CNY, a year-on-year increase of 29.42% and a quarter-on-quarter increase of 19.20%. The net profit for the same quarter was 593 million CNY, up 44.12% year-on-year and 36.86% quarter-on-quarter [3]. - The gross profit margin for Q2 2024 was 43.37%, which is an increase of 3.38 percentage points year-on-year and 3.23 percentage points quarter-on-quarter [3]. Business Segments - The electronic component materials segment is expected to benefit from industry recovery, with continuous development in MLCC products towards miniaturization, high capacitance, high frequency, high reliability, and high voltage [4]. - The company is enhancing its R&D capabilities with the construction of research institutes in Chengdu and Suzhou, which is expected to lead to innovative product offerings and solutions for customers [5]. Future Projections - Revenue growth rates are projected at 29.17%, 33.35%, and 20.05% for 2024 to 2026, while net profit growth rates are expected to be 36.09%, 28.33%, and 21.48% for the same period [6].

证券研究报告 998345887 白色家电Ⅲ 升幅% 1M 3M 12M 相对收益 -9.9 -32.8 9.2 绝对收益 -11.3 -40.4 -3.1 李奕臻 分析师 相关报告 外销景气拉动，Q4 收入加速 增长 2024-03-30 公司快报 2024 年 08 月 30 日 海信家电(000921.SZ) 外销持续景气，收入小幅增长 事件：海信家电公布 2024 年中报。公司 2024H1 实现收入 486.4 亿元，YoY+13.3%；实现归母净利润 20.2 亿元，YoY+34.6%；实现 扣非归母净利润 17.0 亿元，YoY+34.8%。折算 2024Q2 单季度实现 收入 251.6 亿元，YoY+7.0%；实现归母净利润 10.3 亿元， YoY+17.3%；实现扣非归母净利润 8.7 亿元，YoY+16.5%。公司内 销收入增速有所放缓，但海外收入维持高增，我们认为公司出口 景气有望拉动公司稳健增长。 Q2 内销增速所有放缓：根据产业在线数据，2024Q1/2024Q2 海 信 日 立 多 联 机 内 销 额 YoY+8%/-1% ； 海 信 家 用 空 调 内 销 量 YoY+30% ...

Investment Rating - The report maintains a Buy-A rating for the company with a 6-month target price of 49.36 RMB, representing a 5x dynamic price-to-sales ratio for 2024 [5][10] Core Views - The company achieved revenue growth of 18.91% YoY in H1 2024, reaching 9.325 billion RMB, with Q2 revenue growing 14.62% YoY to 5.678 billion RMB [2] - Despite revenue growth, net profit attributable to shareholders declined significantly by 644.59% YoY to -401 million RMB in H1 2024, mainly due to increased investment in large model R&D and industrial application [2][8] - The company's large model technology is gradually entering the application stage, with significant progress in both To B and To C businesses [2][3] Business Performance Education Products and Services - Revenue from education products and services grew 25.14% YoY to 2.86 billion RMB in H1 2024 [3] - The company launched several AI teaching products, including the Spark Smart Blackboard with Spark Large Model 4.0 and the Spark Intelligent Grading Machine [3] - The "Personalized Education" solution has been applied in over 60 cities and districts, with intelligent grading technology used in 14 provinces for college entrance exams [3] Open Platform and Consumer Business - Open platform revenue increased 47.92% YoY to 2.345 billion RMB in H1 2024 [3] - Smart hardware revenue grew 56.61% YoY to 900 million RMB [3] - The platform has attracted over 706,000 developers and 2.48 million applications, with 580,000 large model developers since September 2023 [3] Other B2B Businesses - Smart automotive business revenue increased 65.49% YoY to 352 million RMB [3] - Smart healthcare business revenue grew 18.80% YoY to 228 million RMB [3] - The company has established partnerships with major enterprises across various industries for large model applications [3] Technology Development - The company released Spark Large Model V4.0 in June 2024, achieving performance comparable to GPT-4 Turbo in multiple benchmarks [9] - The Spark Large Model app has reached 140 million downloads on Android [9] - The company launched its first open-source large model, Spark Open Source-13B, in January 2024 [9] - Collaboration with Huawei has resulted in the development of a domestic computing platform capable of supporting trillion-parameter model training [9] Financial Projections - The report forecasts 2024/2025/2026 revenues of 22.826/26.161/29.799 billion RMB [10][11] - Net profit attributable to shareholders is projected to be 513/685/900 million RMB for 2024/2025/2026 [10][11] - The company's gross margin remained stable at 40.19% in H1 2024 [4]

Investment Rating - The report maintains a "Buy-A" investment rating for the company with a 6-month target price of 4.09 CNY, compared to the current stock price of 3.33 CNY [6][10]. Core Insights - The company achieved a revenue of 727 million CNY in the first half of 2024, representing a year-on-year growth of 3.17%. The medical industry segment contributed 693 million CNY, growing by 8.61% [3][4]. - The net profit attributable to shareholders reached 27.376 million CNY, up 14.03% year-on-year, while the net profit excluding non-recurring items was 25.217 million CNY, marking a significant increase of 36.77% [3][4]. - The company has seen a substantial increase in large orders, with orders exceeding 30 million CNY growing by 110.83% compared to the same period last year, enhancing its competitive advantage and market share [4][5]. Financial Performance - The company's gross margin improved to 54.21%, an increase of 2.33 percentage points year-on-year. The revenue breakdown shows software sales at 287 million CNY (YoY +0.02%), technical services at 293 million CNY (YoY +9%), and system integration at 79.67 million CNY (YoY +9.53%) [4]. - The projected revenues for 2024, 2025, and 2026 are 1.857 billion CNY, 2.125 billion CNY, and 2.416 billion CNY, respectively, with net profits expected to be 181 million CNY, 266 million CNY, and 337 million CNY [10][12]. Strategic Developments - The company is actively expanding its collaboration with Philips, with over 50 ongoing projects for its HI-HIS product, primarily in tertiary hospitals. The product has already been implemented in 12 hospitals [5]. - The company has successfully launched the "Jiangxi Province Grassroots AI-Assisted Smart Medical System," which is the first of its kind in the country, covering extensive healthcare functionalities across the province [5].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 15.47 CNY for the next six months, corresponding to a PE valuation of 13x for 2024 [4][12]. Core Views - The company reported a revenue of 3.37 billion CNY for the first half of 2024, a year-over-year decrease of 5.0%, and a net profit of 380 million CNY, down 3.0% year-over-year. In Q2 2024, the revenue was 1.78 billion CNY, down 12.6% year-over-year, and the net profit was 260 million CNY, down 11.7% year-over-year [2][3]. - Despite external pressures from the real estate downturn and weak consumer demand, the company is focusing on enhancing its competitive advantages through digital transformation and platform development [2][3]. - The company has maintained a strong cash position, with cash and cash equivalents plus trading financial assets amounting to 5.67 billion CNY, representing 58% of total assets [4]. Financial Performance Summary - The gross margin for Q2 2024 was 40.0%, an increase of 0.8 percentage points year-over-year, influenced by the company's product platform development and competitive pricing pressures [3]. - The net profit margin for Q2 2024 was 14.8%, up 0.2 percentage points year-over-year, while the non-recurring net profit margin decreased by 1.2 percentage points year-over-year [3]. - The company has increased its sales, management, and R&D expense ratios by 1.7%, 0.4%, and 0.3% year-over-year, respectively, indicating a commitment to strengthening its market position [3]. Future Projections - The company is expected to achieve earnings per share (EPS) of 1.19 CNY, 1.26 CNY, and 1.33 CNY for the years 2024, 2025, and 2026, respectively [4][12]. - Revenue projections for the upcoming years are 7.54 billion CNY in 2024, 7.95 billion CNY in 2025, and 8.36 billion CNY in 2026, reflecting a gradual recovery [12].

Investment Rating - The report assigns a "Buy - A" investment rating to the company, with a 12-month target price of 23.20 CNY, compared to the current stock price of 19.30 CNY [2][9]. Core Insights - The company's overall performance has significantly improved, with a 13.70% year-on-year increase in revenue to 649 million CNY in the first half of 2024, and a return to profitability with a net profit of 16.16 million CNY [1][2]. - The company has launched over 160 new products in its Life Sciences division and achieved a revenue growth of approximately 18% in this segment [2]. - The In Vitro Diagnostics division has seen a 32% year-on-year revenue growth, supported by the acquisition of new medical device certifications and an extensive network of over 350 channel partners [2]. - The company has developed a supply chain solution for semaglutide in its Biopharmaceutical division, achieving significant production capacity [2]. - The newly established Microfluidics division has successfully developed a respiratory infection detection kit, receiving EU CE certification [2]. - The International Business division has expanded its reach to over 60 countries, enhancing global delivery capabilities [2]. - The company is expected to achieve full profitability in the second half of 2024 as revenue continues to grow [7]. Financial Performance Summary - In the first half of 2024, the company reported a gross margin of 70.74%, with a slight year-on-year decline but stable compared to the second half of 2023 [7]. - The company’s sales expenses amounted to 218 million CNY, while management and R&D expenses were 109 million CNY and 142 million CNY, respectively, showing a reduction compared to previous periods [7]. - Revenue projections for 2024 to 2026 are estimated at 1.563 billion CNY, 1.915 billion CNY, and 2.323 billion CNY, with corresponding net profits of 97.6 million CNY, 232.8 million CNY, and 345.5 million CNY [9][10].

Investment Rating - The report maintains a "Buy-A" investment rating for the company with a target price of 5.99 CNY for the next six months [5][6]. Core Insights - The company reported a revenue of 3.406 billion CNY for the first half of 2024, a year-on-year increase of 3.26%, while the net profit attributable to shareholders decreased by 54.60% to 100.5 million CNY [1]. - The overseas revenue for the first half of 2024 reached 2.171 billion CNY, marking a year-on-year growth of 19.34% [2]. - The company's gross profit margin improved to 32.08%, an increase of 2.23 percentage points, primarily due to a higher proportion of overseas business [2]. - The global LED display market is projected to grow at a compound annual growth rate (CAGR) of 13.78% from 2021 to 2026, with small-pitch displays growing at 23.65% and micro-pitch displays at 40.08% [3]. - The company has achieved significant technological advancements in Mini/Micro LED products, addressing various technical challenges and planning to expand production capacity to 6,000KK per month by the end of 2024 [4]. Financial Summary - Revenue projections for the company are estimated at 8.077 billion CNY, 9.047 billion CNY, and 10.132 billion CNY for 2024, 2025, and 2026 respectively, with net profits expected to be 272 million CNY, 367 million CNY, and 751 million CNY for the same years [5][10]. - The company’s earnings per share (EPS) is projected to increase from 0.25 CNY in 2024 to 0.69 CNY in 2026 [10]. - The price-to-earnings (PE) ratio is expected to decrease from 20.6 in 2024 to 7.5 in 2026, indicating a potential increase in value [10].